2022 - Research.com Best Scientist Award
2015 - Fellow of the American Association for the Advancement of Science (AAAS)
His primary areas of study are Breast cancer, Internal medicine, Oncology, Cancer and Surgery. His Breast cancer study integrates concerns from other disciplines, such as Cancer research and Metastasis. His research investigates the connection with Internal medicine and areas like Gynecology which intersect with concerns in Epidemiology.
His Oncology study incorporates themes from Retrospective cohort study, Pathology, Proportional hazards model, Hazard ratio and Survival analysis. His study ties his expertise on Odds ratio together with the subject of Cancer. His Surgery research is multidisciplinary, relying on both Gastroenterology and Disease.
His main research concerns Internal medicine, Breast cancer, Oncology, Cancer and Chemotherapy. His Internal medicine study combines topics from a wide range of disciplines, such as Gastroenterology and Surgery. The various areas that Gabriel N. Hortobagyi examines in his Surgery study include Taxane and Carcinoma.
His Breast cancer research incorporates elements of Cancer research, Pathology, Gynecology, Stage and Radiation therapy. His work carried out in the field of Oncology brings together such families of science as Neoadjuvant therapy, Clinical trial, Trastuzumab, Anthracycline and Disease. His studies in Cancer integrate themes in fields like Retrospective cohort study and Hazard ratio.
The scientist’s investigation covers issues in Internal medicine, Breast cancer, Oncology, Cancer and Cancer research. His Internal medicine study focuses mostly on Chemotherapy, Metastatic breast cancer, Proportional hazards model, Stage and Hazard ratio. Within one scientific family, Gabriel N. Hortobagyi focuses on topics pertaining to Surgery under Breast cancer, and may sometimes address concerns connected to Adverse effect.
In his study, Capecitabine and Neoadjuvant therapy is inextricably linked to Trastuzumab, which falls within the broad field of Oncology. The concepts of his Cancer study are interwoven with issues in Placebo, Cohort and Bioinformatics. His Cancer research research is multidisciplinary, incorporating perspectives in Immune checkpoint, Immunotherapy, Cancer cell, Cancer stem cell and Immunology.
His primary areas of study are Internal medicine, Breast cancer, Oncology, Cancer and Proportional hazards model. Gabriel N. Hortobagyi has researched Internal medicine in several fields, including Gynecology and Surgery. His research integrates issues of Cancer research, Chemotherapy regimen, Survival rate, Retrospective cohort study and Stage in his study of Breast cancer.
His Oncology research incorporates themes from Neoadjuvant therapy, Trastuzumab, Inflammatory breast cancer, Disease and Cohort. His Cancer research includes themes of Incidence, PARP inhibitor and Bioinformatics. His study in Chemotherapy is interdisciplinary in nature, drawing from both Taxane and Estrogen receptor.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy
Roman Rouzier;Charles M. Perou;W. Fraser Symmans;Nuhad Ibrahim.
Clinical Cancer Research (2005)
PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients
Yoichi Nagata;Keng Hsueh Lan;Xiaoyan Zhou;Ming Tan.
Cancer Cell (2004)
Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial
Kathy S Albain;William E Barlow;Steven Shak;Gabriel N Hortobagyi.
Lancet Oncology (2010)
Future of Cancer Incidence in the United States: Burdens Upon an Aging, Changing Nation
Benjamin D. Smith;Grace L. Smith;Arti Hurria;Gabriel N. Hortobagyi.
Journal of Clinical Oncology (2009)
Significantly Higher Pathologic Complete Remission Rate After Neoadjuvant Therapy With Trastuzumab, Paclitaxel, and Epirubicin Chemotherapy: Results of a Randomized Trial in Human Epidermal Growth Factor Receptor 2–Positive Operable Breast Cancer
Aman U. Buzdar;Nuhad K. Ibrahim;Deborah Francis;Daniel J. Booser.
Journal of Clinical Oncology (2005)
Clinical Course of Breast Cancer Patients With Complete Pathologic Primary Tumor and Axillary Lymph Node Response to Doxorubicin-Based Neoadjuvant Chemotherapy
Henry M. Kuerer;Lisa A. Newman;Terry L. Smith;Fred C. Ames.
Journal of Clinical Oncology (1999)
Phase II Trial of Taxol, an Active Drug in the Treatment of Metastatic Breast Cancer
Frankie Ann Holmes;Ronald S. Walters;Richard L. Theriault;Aman U. Buzdar.
Journal of the National Cancer Institute (1991)
Efficacy of Pamidronate in Reducing Skeletal Complications in Patients with Breast Cancer and Lytic Bone Metastases
Gabriel N. Hortobagyi;Richard L. Theriault;Lester Porter;Douglas Blayney.
The New England Journal of Medicine (1996)
Circulating Tumor Cells: A Novel Prognostic Factor for Newly Diagnosed Metastatic Breast Cancer
Massimo Cristofanilli;Daniel F. Hayes;G. Thomas Budd;Mathew J. Ellis.
Journal of Clinical Oncology (2005)
The HER-2 Receptor and Breast Cancer: Ten Years of Targeted Anti–HER-2 Therapy and Personalized Medicine
Jeffrey S. Ross;Elzbieta A. Slodkowska;W. Fraser Symmans;Lajos Pusztai.
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: